A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-30. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Lake Afrera (in Italian Lake Giuletti) is a hypersaline lake in northern Ethiopia. Located in Kilbet Rasu, Afar Region, it is one of the lakes of the Danakil Depression. It has a surface of 117 km2 (45 mi2) and holds 2.4 km3 of brine. The maximal depth of Lake Afdera is 80 m in the northern basin and 76 m in the southern basin. No major river drains the lake. It is fed by hot springs along the shores of the lakes. It is also known as Lake Giulietti, the name Raimondo Franchetti gave it after the Italian explorer Giuseppe Maria Giulietti was slain by Afars southwest of the lake. Another name for this body of water is Lake Egogi (or Egogi Bad), which is the name L. M. Nesbitt's Afar guide gave it when the Italian explorer became the first European to see it in 1928. The single island in Lake Afrera, Franchetti Island (also known as "Deset"), located in the southern part of the lake, is considered the lowest-lying island in the world. Unlike other saline lakes in Ethiopia (e.g., Lakes Abijatta, Shala, and Chitu), the pH of Lake Afrera is low and in the acidic range. Although little studied, a few species of fish are hosted by Lake Afrera, including two endemics: Danakilia franchettii (a cichlid) and Aphaniops stiassnyae (syn. Lebias stiassnyae; a pupfish).
== Side effects == The development of anti-nuclear antibodies (ANA) has been found in 10 to 30% of patients under treatment with acebutolol. A systemic disease with arthralgic pain and myalgias has been observed in 1%. A lupus erythematosus-like syndrome with skin rash and multiforme organ involvement is even less frequent. The incidence of both ANA and symptomatic disease under acebutolol is higher than under propranolol. Female patients are more likely to develop these symptoms than male patients. Some few cases of hepatotoxicity with increased liver enzymes (ALT, AST) have been seen. Altogether, 5 to 6% of all patients treated have to discontinue acebutolol due to intolerable side effects. When possible, the treatment should be discontinued gradually in order to avoid a withdrawal syndrome with increased frequency of angina and even precipitation of myocardial infarction.
A primordial element is a chemical element with at least one primordial nuclide. There are 251 stable primordial nuclides and 35 radioactive primordial nuclides, but only 80 primordial stable elements—hydrogen through lead, atomic numbers 1 to 82, except for technetium (43) and promethium (61)—and three radioactive primordial elements—bismuth (83), thorium (90), and uranium (92). If plutonium (94) turns out to be primordial (specifically, the long-lived isotope 244Pu), then it would be a fourth radioactive primordial, though practically speaking it would still be more convenient to produce synthetically. Bismuth's half-life is so long that it is often classed with the 80 stable elements instead, since its radioactivity is not a cause for concern. The number of elements is smaller than the number of nuclides, because many of the primordial elements are represented by multiple isotopes. See chemical element for more information.
Sources: en.wikipedia.org
=== Electrostatic and hydrophobic interactions === Electrostatic interactions can form nanogels through the combination of anionic and cationic polymers in an aqueous solution. The size and surface charge of the resulting nanogels can be modulated by changing the molecular weight or the charge ratio of the two different polymers. Ionotropic gelation can also leverage electrostatic interactions between multivalent anions and cations to form nanogels. Hydrophobic interactions rely heavily on physical crosslinking to form nanogels. In this method, hydrophobic groups are added to hydrophilic polymers in an aqueous solution to induce their self-assembly into nanogels. When thiolated polymers (thiomers) are used for this preparation process, nanogels can be further stabilized by the formation of inter- and intrachain disulfide bonds due to oxidation. In the following the oppositely charged oligo- or polymers can even be removed.
Further shell closures beyond the main island of stability in the vicinity of Z = 112–114 may give rise to additional islands of stability. Although predictions for the location of the next magic numbers vary considerably, two significant islands are thought to exist around heavier doubly magic nuclei; the first near 354126 (with 228 neutrons) and the second near 472164 or 482164 (with 308 or 318 neutrons). Nuclides within these two islands of stability might be especially resistant to spontaneous fission and have alpha decay half-lives measurable in years, thus having comparable stability to elements in the vicinity of flerovium. Other regions of relative stability may also appear with weaker proton shell closures in beta-stable nuclides; such possibilities include regions near 342126 and 462154. Substantially greater electromagnetic repulsion between protons in such heavy nuclei may greatly reduce their stability, and possibly restrict their existence to localized islands in the vicinity of shell effects. This may have the consequence of isolating these islands from the main chart of nuclides, as intermediate nuclides and perhaps elements in a "sea of instability" would rapidly undergo fission and essentially be nonexistent. It is also possible that beyond a region of relative stability around element 126, heavier nuclei would lie beyond a fission threshold given by the liquid drop model and thus undergo fission with very short lifetimes, rendering them essentially nonexistent even in the vicinity of greater magic numbers.
During 1973–2013, Khavinson et al., extracted from various organs over 20 complexes of physiologically active peptides, as well as 15 others synthesized from amino acids, (di-, tri-, tetrapeptides), all being covered by patents in many countries including the US, Canada, Australia, Europe, Japan, Korea, Israel, etc. After many years of experimental and clinical studies, six medicinal peptide preparations were permitted for medical use in the USSR, Russia, and afterward in the CIS countries. They were primarily to be used by the military medical service. These are ‘Thymalin’- a preparation of the thymus, being a cellular immunity regulator; ‘Epithalamin’ — a preparation from the pineal gland — regulator of the endocrine system, which restores melatonin, (with no analogues worldwide) ‘Cortexin’ — a preparation from the cerebral cortex, brain function regulator; ‘Prostatilen’ or ‘Samprost’ or ‘Vitaprost’ — a preparation from the prostate gland, regulator of prostate function; ‘Retinalamin’ — a preparation from the retina, partially restores functions of the retina in case of laser lesions and degenerative diseases, has no analogues worldwide; ‘Thymogen’ — a dipeptide EW, being first extracted from ‘Thymalin’, then synthesized from amino acids, regulates immunity. These medicinal peptide preparations were first used to restore immune functions of the brain, endocrine system, retina, etc.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.